My health: Whose responsibility? Low-dose aspirin and older people

Expert Review of Cardiovascular Therapy

Volumn 4, Issue 5, 2006, Pages 755-764

  Elwood, Peter ^a   Longley, Marcus ^b   Morgan, Gareth ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF GLAMORGAN   (United Kingdom)

Author keywords

Aspirin; Health promotion; Older subjects; Prophylaxis; Vascular risk

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTICOAGULANT AGENT; CLOPIDOGREL; DIPYRIDAMOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; WARFARIN;

AGED; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG FORMULATION; DRUG INDICATION; ELDERLY CARE; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE POLICY; HEALTH PROMOTION; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; OCCLUSIVE CEREBROVASCULAR DISEASE; OUTCOMES RESEARCH; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRIMARY PREVENTION; RESPONSIBILITY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT FAILURE; UNITED KINGDOM;

AGED; ANTICOAGULANTS; ASPIRIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HEALTH; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; NEOPLASMS; SELF CARE; VASCULAR DISEASES;

EID: 33750945103     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.4.5.755     Document Type: Review

References (87)

1. Sneader W. The discovery of aspirin: a reappraisal. Br. Med J. 321, 1591-1594 (2000).
2. Donne A. De l'origine des globules du sang, deleur mode de formation et de leur fin. Compt. Rend Acad. Sc. 14, 366-368 (1842).
3. Osler W. An account of certain organisms occuring in the liquor sanguinis. Proc. R. Soc. Lond. 5, 692-734 (1874).
4. Haerem. JW. Platelet aggregates and mural microthrombin in the early stages of acute phase of coronary disease. Thromb. Res. 5, 243 (1974).
5. Davies MJ, Thomas AC. Thrombosis and acute coronary-artery lesions in sudden cardiac ischaemic death. N. Engl. J. Med 10, 1137-1140 (1984).
6. O'Brien JR. The adhesiveness of native platelets: some anti-adhesive drugs and their mode of action. Proc. VII Congress Europ. Soc. Haem. 51-56 (1961).
7. Morris CDW. Acetylsalicylic acid and platelet stickiness. Lancet I, 279-280 (1967).
8. O'Brien JR. Effects of salicylates on human platelets. Lancet I, 779-783 (1968).
9. Stuart RK. Platelet function studies in human beings receiving 300 mg of aspirin per day. J. Lab. Clin. Med 75, 463-471 (1970).
10. Elwood PC, Cochrane AI, Burr M et al. A randomised, controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br. Med J. I, 436-440 (1974).
11. Collins R, MacMahon S, Flather M et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. Br. Med J. 313, 652-659 (1996).
12. Antiplatelet Trialists Collaboration. Collaborative overview of random trials of anti-platelet therapy - prevention of death, myocardial infarction and stroke by prolonged anti-platelet therapy in various categories of patients. Br. Med. J. 308, 81-106 (1994).
13. Antiplatelet Trialists Collaboration. Collaborative meta-analysis of randomised trials of platelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. Br. Med J. 324, 71-86 (2002).
14. Sanmuganathan PS, Gjahramani P, Jackson PR et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 85, 265-271 (2001).
15. Hankey GJ, Warlow CP, Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 1, 457-463 (1999).
16. Tran H, Anand SS. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease and peripheral arterial disease. JAMA 292, 1867-1874 (2004).
17. Kmietowicz Z. Aspirin benefits patients with stroke - but only just. Br. Med. J. 314, 1646 (1997).
18. Chinese Acute Stroke Collaborative Group. (CAST) Chinese Acute Stroke Collaborative Group: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 349, 1641-1647 (1997).
19. International Stroke Trial Collaborative Group. A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 349, 1569-1581 (1997).
20. Edvardsson N, Juul-Moller S, Omblus R et al. Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. J. Int. Med. 254, 95-101 (2003).
21. Hellemons BSP, Langenberg M, Lodder J et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. Br. Med. J. 319, 958-964 (1999).
22. Stein PD, Hull RD, Kayali F et al. Venous thromboembolism according to age: the impact of an ageing population. Arch. Int. Med. 164, 2260-2265 (2004).
23. Anonymous. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 355, 1295-1302 (2000).
24. Col NF, Yasrzbski J, Gore JM et al. Does aspirin consumption affect the presentation or severity of acute myocardial infarction? Arch. Int. Med. 155, 1396-1389 (1995).
25. Garcia-Dorado D, Therous P, Tornos P et al. Previous aspirin use may attenuate the severity of the manifestation of acute ischaemic syndromes; Circulation 92, 1743-1748 (1995).
26. Steering Committee of the Physician's Health Study Research Group. Final report on the aspirin component of the on-going Physician's Health Study. N. Engl. J. Med. 321, 129-135 (1989).
27. Glynn RJ, Buring JE, Manson JE et al. Adherence to aspirin in the prevention of myocardial infarction: the Physicians Health Study. Arch. Int. Med. 154, 2649-2657 (1994).
28. Gum PA, Kottke-Marchant K, Poggio ED et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol. 88, 230-235 (2001).
29. Schwartz KA, Schwartz DE, Ghosheh K et al. Compliance as critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am. J. Cardiol. 95, 973-975 (2005).
30. Elwood PC, Beswick A, Pickering J et al. Platelet tests in the prediction of myocardial infarction and stroke: evidence from the Caerphilly study. Br. J. Haematol. 113, 514-520 (2001).
31. Elwood PC, Pickering J, O'Brien J et al. Bleeding time, stroke and myocardial infarction: the Caerphilly prospective study. Platelets 14, 139-141 (2003).
32. Gum PA, Kottke-Marchant K, Welsh PA et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll, Cardiol, 41, 961-965 (2003)
33. Peto R, Gray R, Collins R et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br. Med. J. 296, 313-316 (1998).
34. Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 351, 233-241 (1998).
35. Hansson I, Zanchetti A, Carruthers SC et al Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351, 1755-1762 (1998).
36. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 357, 89-95 (2001).
37. Juul-Moller S, Edvardsson N, Jahnmatz B et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with chronic angina pectoris. The Swedish Angina Pectoris Trial (SAPAT) Group. Lancet 340, 1421-1425 (1992).
38. Elwood PC. Aspirin: past, present and future. Clin. Med 1(2), 1132-1137 (2001).
39. Elwood PC, Morgan G, Brown G, Pickering J. Aspirin for everyone older than 50? Br. Med J. 330, 1440-1441 (2005).
40. Baigent C. Aspirin for everyone older than 50? Br. Med J. 330, 1442-1443 (2005).
41. Gollapudi RR, Tierstein PS, Stevenson DD et al. Aspirin sensitivity: implications for patients with coronary artery disease. JAMA 292, 3017-3023 (2004).
42. Hernandez-Dias, Garcia Rodriguez LA. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiological studies. J. Clin. Epidemiol. 55, 157-163 (2002).
43. Garcia Rodriquez LA, Hernandez-Dias S, Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiological studies. Br. J. Clin. Pharmacol. 52, 563-571 (2001).
44. Bollini P, Garcia Rodriguez LA, Perez Gutthann S et al. The impact of research quality and study design on epidemiological estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch. Int. Med. 152, 1289-1295 (1992).
45. Hernandez-Diaz S, Garcia Rodriguez LA. Association between non-steroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/ perforation: an overview of epidemiological studies published in the 1980s. Arch. Int. Med. 160, 2093-2099 (2000).
46. Strachan DP, Mendall MA, Carrington D et al. Relation of Helicobacter pylori infection to 13-year mortality and incident ischemic heart disease in the Caerphilly prospective heart disease study. Circulation 98, 1286-1290 (1998).
47. Lanas A, Rodrigo L, Marquez JL et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment. Pharmacol. Ther. 16, 779-786 (2002).
48. Chan KL, Chung SCS, Suen BY et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N. Engl. J. Med. 344, 967-973 (2001).
49. Lai KC, Larn SK, Chu KM et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med. 346, 2033-2038 (2002).
50. He J, Whelton PK. Vu B et al. Aspirin and risk of haemorrhagic stroke. A meta-analysis of randomised controlled trials. JAMA 280, 1930-1935 (1998).
51. Lanas A, Rodrigo L, Marquez JL et al. Low frequency of upper intestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDs and omeprazole. Scand. J. Gastroenterol, 38, 693-700 (2003).
52. Kimmey MB, Lanas A. Review article: appropriate use of proton pump inhibitors with traditional nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors. Aliment. Pharmacol. Ther. 19, 60-65 (2004).
53. Bogentoft C, Carlsson I, Ekenved G et al. The influence of food on the absorption of acetylsalicylic acid from enteric-coated dosage forms. Eur. J. Clin. Pharm. 14, 351-355 (1978).
54. Muir N, Nichols JD, Stillings MR et al. Comparative bioavailability of aspirin and paracetamol following single dose administration of soluble and plain tablets. Curr. Med. Res. Opin. 13, 491-500 (1997).
55. Aihie AP Halpern SM, Streete PJ et al. Slow release aspirin in the elderly. J. Roy. Soc. Med. 87, 183 (1994).
56. Woollard M, Smith A, Elwood P. Pre-hospital aspirin for suspected myocardial infarction and acute coronary syndromes: a headache for paramedics? Emerg. Med. J. 18, 478-481 (2001).
57. Brecker SJD. Early aspirin in myocardial infarction. Lancet 335, 923 (1990).
58. Norfolk Health: East Norfolk Health Comission. In: Guidelines for practical procedures with a suspected heart attack. (1996).
59. Berglund U, Wallentin L. Persistent inhibition of platelet function during long-term treatment with 75mg acetylsalicylic acid daily in men with unstable coronary artery disease. Eur. Heart J. 12, 428-433 (1991).
60. CAPRIE Steering Committee. Randomised, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events. (CAPRIE). Lancet 348, 1329-1336 (1996).
61. Bhatt DL, Fox KAA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherosclerotic events. N. Engl. J. Med. 354, 1706-1717 (2006).
62. Leonardi-Bee J, Bath PM, Bopusser MG et al. Dipyridamole for preventing recurrent ischaemic stroke and other vascular events: a meta-analysis of individual patient data from randomised controlled trials. Stroke 36, 162-168 (2005).
63. De Schryver EL, Algra A. Gijn J. Cochrane review: dipyridamole for preventing major vascular events in patients with vascular disease. Stroke 34, 2072-2080 (2003).
64. Collins R, MacMahon S, Flather M et al. Clinical eflects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. Br. Med. J. 313, 652-659 (1996).
65. Anand SS, Yusef S. Oral anticoagulants in patients with coronary artery disease. J. Am. Coll. Candiol. 41, 62S-69S (2003).
66. Skoog I, Nilsson L, Palmertz B, Andreasson LA, Svanborg A. A population-based study of dementia in 85-year-olds. N, Engl. J. Med. 328, 153-158 (1993).
67. Jorm AF, Jolley D. The incidence of dementia; a meta-analysis. Neurology 51, 728-733 (1998).
68. Meyer JS, Rogers RL, McClintic K et al. Randomised clinical trial of aspirin therapy in multi-infarct dementia. A pilot study. J. Am. Geriat. Soc. 37, 549-555 (1989).
69. Richards M, Meade TW, Peart S et al. Is there evidence for a protective effect of antithrombotic medication on cognitive function in men at risk of cardiovascular disease? Some preliminary findings. J Neurol. Neurosurg. Psychiatry 62, 269-272 (1997).
70. Stewart WF, Kawas C, Corrada M et al. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48, 626-632 (1997)
71. Brietner JC, Gau BA, Welsh KA et al. Inverse association of anti-inflammatory treatment and Alzheimer's disease: initial results of a cotwin control study. Neurology 44, 227-232 (1994).
72. Garcia Rodriguez LA, Huerta-Alvarez C. Reduced incidence of colorectal ademomas among long term users of nonsteroidal anti-inflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology 11, 376-381 (2000).
73. Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer and polyps of the large bowel. Cancer 72, 1171-1177 (1993).
74. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic and clinical issues. J. Natl. Cancer Inst. 94, 252-266 (2002).
75. Sandler RS, Halabi S, Baron JA et al. A randomised trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med 348, 883-890 (2003).
76. Baron JA, Cole BF, Sandler RS et al. A randomised trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348, 891-899 (2003).
77. Pierpoint WS. The natural history of salicylic acid. Interdisciplinary Science Reviews 22, 45-52 (1997).
78. Mur LAJ, Brown IR, Darby et al. A loss of resistance to avirulent bacterial pathogens in tobacco is associated with the attenuation of a salicylic acid-potentiated oxidative burst. Plant J. 23, 609-621 (2000).
79. Williams AR, Balasooriya BA, Day DW. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut 23, 835-842 (1982).
80. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. Br. Med. J. 320, 705-708 (2000).
81. Hayden M, Pignone M, Phillips C et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med. 136, 161-172 (2002).
82. Rothwell P, Coull AJ, Silver L et al. Population-based study of event-rate, incidence, case-fatality and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 366, 1773-1783 (2005).
83. Dalen J. An apple a day or an aspirin a day? Arch. Int. Med. 151, 1066-1068 (1991).
84. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. Br. Med. J. 326, 1419-1424 (2003).
85. Lamotte M, Annemans I, Evers T, Kubin M. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. Ann. Intern. Med. 144, 326-336 (2006).
86. Choosing health: making healthier choices easier. In: Public Health White Paper'. Department of Health, UK Government White Paper, London, UK (2004).
87. King's Fund. In: Public Attitudes to Public Health Policy. King's Fund Publications, London, UK (2004).